167 related articles for article (PubMed ID: 26050023)
1. The correlation between EGFR mutation status and the risk of brain metastasis in patients with lung adenocarcinoma.
Li B; Sun SZ; Yang M; Shi JL; Xu W; Wang XF; Song MM; Chen HM
J Neurooncol; 2015 Aug; 124(1):79-85. PubMed ID: 26050023
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma.
Ma X; Zhu H; Guo H; Han A; Wang H; Jing W; Zhang Y; Kong L; Yu J
Oncotarget; 2016 Dec; 7(49):81906-81917. PubMed ID: 27626317
[TBL] [Abstract][Full Text] [Related]
3. A retrospective analysis in patients with EGFR-mutant lung adenocarcinoma: is EGFR mutation associated with a higher incidence of brain metastasis?
Han G; Bi J; Tan W; Wei X; Wang X; Ying X; Guo X; Zhou X; Hu D; Zhen W
Oncotarget; 2016 Aug; 7(35):56998-57010. PubMed ID: 27486770
[TBL] [Abstract][Full Text] [Related]
4. Impact of epidermal growth factor receptor mutations on intracranial treatment response and survival after brain metastases in lung adenocarcinoma patients.
Hsiao SH; Lin HC; Chou YT; Lin SE; Kuo CC; Yu MC; Chung CL
Lung Cancer; 2013 Sep; 81(3):455-461. PubMed ID: 23871711
[TBL] [Abstract][Full Text] [Related]
5. Exon 19 deletion of epidermal growth factor receptor is associated with prolonged survival in brain metastases from non-small-cell lung cancer.
Li H; Zhang X; Cao J; Su P; Lian J; Song X; Yang W; Han S; Xi Y; Wang Y
Tumour Biol; 2015 Dec; 36(12):9251-8. PubMed ID: 26091796
[TBL] [Abstract][Full Text] [Related]
6. How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations?
Hata A; Katakami N; Yoshioka H; Kunimasa K; Fujita S; Kaji R; Notohara K; Imai Y; Tachikawa R; Tomii K; Korogi Y; Iwasaku M; Nishiyama A; Ishida T
J Thorac Oncol; 2013 Jan; 8(1):89-95. PubMed ID: 23242440
[TBL] [Abstract][Full Text] [Related]
7. Analysis of the benefit of sequential cranial radiotherapy in patients with EGFR mutant non-small cell lung cancer and brain metastasis.
Byeon S; Ham JS; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Med Oncol; 2016 Aug; 33(8):97. PubMed ID: 27447711
[TBL] [Abstract][Full Text] [Related]
8. Radiotherapy for asymptomatic brain metastasis in epidermal growth factor receptor mutant non-small cell lung cancer without prior tyrosine kinase inhibitors treatment: a retrospective clinical study.
Liu S; Qiu B; Chen L; Wang F; Liang Y; Cai P; Zhang L; Chen Z; Liu S; Liu M; Liu H
Radiat Oncol; 2015 May; 10():118. PubMed ID: 26014133
[TBL] [Abstract][Full Text] [Related]
9. Survival but not brain metastasis response relates to lung cancer mutation status after radiosurgery.
Shin SM; Cooper BT; Chachoua A; Butler J; Donahue B; Silverman JS; Kondziolka D
J Neurooncol; 2016 Feb; 126(3):483-91. PubMed ID: 26520640
[TBL] [Abstract][Full Text] [Related]
10. Brain metastasis features and association with tumor epidermal growth factor receptor mutation in patients with adenocarcinoma of the lung.
Luo YH; Wu CH; Huang CY; Wu CW; Wu WS; Lee YC; Whang-Peng J; Chen YM
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e440-e448. PubMed ID: 27550395
[TBL] [Abstract][Full Text] [Related]
11. Effects of epidermal growth factor receptor-tyrosine kinase inhibitors alone on EGFR-mutant non-small cell lung cancer with brain metastasis.
Zhang Q; Zhang X; Yan H; Jiang B; Xu C; Yang J; Chen Z; Su J; Wu YL; Zhou Q
Thorac Cancer; 2016 Nov; 7(6):648-654. PubMed ID: 27755835
[TBL] [Abstract][Full Text] [Related]
12. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
13. Impact of KRAS and EGFR gene mutations on recurrence and survival in patients with surgically resected lung adenocarcinomas.
Sonobe M; Kobayashi M; Ishikawa M; Kikuchi R; Nakayama E; Takahashi T; Menju T; Takenaka K; Miyahara R; Huang CL; Okubo K; Bando T; Date H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S347-54. PubMed ID: 21607772
[TBL] [Abstract][Full Text] [Related]
14. Impact of systematic EGFR and KRAS mutation evaluation on progression-free survival and overall survival in patients with advanced non-small-cell lung cancer treated by erlotinib in a French prospective cohort (ERMETIC project--part 2).
Cadranel J; Mauguen A; Faller M; Zalcman G; Buisine MP; Westeel V; Longchampt E; Wislez M; Coudert B; Daniel C; Chetaille B; Michiels S; Blons H; Solassol J; De Fraipont F; Foucher P; Urban T; Lacroix L; Poulot V; Quoix E; Antoine M; Danton G; Morin F; Chouaid C; Pignon JP
J Thorac Oncol; 2012 Oct; 7(10):1490-502. PubMed ID: 22982650
[TBL] [Abstract][Full Text] [Related]
15. Radiotherapy in lung adenocarcinoma with brain metastases: effects of activating epidermal growth factor receptor mutations on clinical response.
Gow CH; Chien CR; Chang YL; Chiu YH; Kuo SH; Shih JY; Chang YC; Yu CJ; Yang CH; Yang PC
Clin Cancer Res; 2008 Jan; 14(1):162-8. PubMed ID: 18172267
[TBL] [Abstract][Full Text] [Related]
16. Assessment of prognostic scores of brain metastases from lung adenocarcinoma with EGFR mutations.
Li H; Lian J; Jin H; Wang W; Cao J; Zhang X; Song X; Jia S; Jia H; Ren J; Han S; Yang W; Xi Y; Lan S
J Neurooncol; 2017 May; 133(1):129-135. PubMed ID: 28391386
[TBL] [Abstract][Full Text] [Related]
17. [Impacts of EGFR 19 exon mutations on brain metastases in treatment-naïve patients with lung adenocarcinoma].
Wang WL; Li HW; Cao JZ; Zhang XQ; Song X; Jia SF; Jia HX
Zhonghua Zhong Liu Za Zhi; 2017 Oct; 39(10):744-748. PubMed ID: 29061017
[No Abstract] [Full Text] [Related]
18. Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.
Lee DW; Shin DY; Kim JW; Keam B; Kim TM; Kim HJ; Kim DW; Wu HG; Paek SH; Kim YW; Heo DS; Kim DG; Lee SH
Lung Cancer; 2014 Dec; 86(3):363-8. PubMed ID: 25453849
[TBL] [Abstract][Full Text] [Related]
19. The impact of EGFR mutations on the incidence and survival of stages I to III NSCLC patients with subsequent brain metastasis.
Chang WY; Wu YL; Su PL; Yang SC; Lin CC; Su WC
PLoS One; 2018; 13(2):e0192161. PubMed ID: 29447182
[TBL] [Abstract][Full Text] [Related]
20. Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic non-small-cell lung cancer.
Lee VH; Tin VP; Choy TS; Lam KO; Choi CW; Chung LP; Tsang JW; Ho PP; Leung DK; Ma ES; Liu J; Shek TW; Kwong DL; Leung TW; Wong MP
J Thorac Oncol; 2013 Sep; 8(9):1148-55. PubMed ID: 23945384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]